Cholecystokinin and gastrin receptors targeting in gastrointestinal cancer.

[1]  A. Funakoshi,et al.  Association of cholecystokinin A receptor gene polymorphism with cholelithiasis and the molecular mechanisms of this polymorphism , 2002, Journal of Gastroenterology.

[2]  J. Reubi,et al.  Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors , 2012, Molecular and Cellular Endocrinology.

[3]  D. Saluja,et al.  Synthesis and Evaluation of a Fluorescent Non‐Peptidic Cholecystokinin‐B/Gastrin Receptor Specific Antagonist for Cancer Cell Imaging , 2012, Chembiochem : a European journal of chemical biology.

[4]  T. Singh,et al.  Expression profile of cholecystokinin type-A receptor in gallbladder cancer and gallstone disease. , 2011, Hepatobiliary & pancreatic diseases international : HBPD INT.

[5]  W. Oyen,et al.  Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  A. Ryberg,et al.  Expression of multiple forms of 3'-end variant CCK2 receptor mRNAs in human pancreatic adenocarcinomas , 2011, BMC Research Notes.

[7]  Snigdhamayee Praharaj,et al.  Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor. , 2010, Future oncology.

[8]  I. Drozdov,et al.  The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development , 2010, Regulatory Peptides.

[9]  R. Valkema,et al.  Preclinical and clinical studies of peptide receptor radionuclide therapy. , 2010, Seminars in nuclear medicine.

[10]  Otto C. Boerman,et al.  Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors , 2010, Amino Acids.

[11]  L. Miller,et al.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor , 2010, British journal of pharmacology.

[12]  T. Meyer,et al.  A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. , 2010, European journal of cancer.

[13]  M. Takei,et al.  Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells. , 2010, Biological & pharmaceutical bulletin.

[14]  T. Meyer,et al.  Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice , 2010, Molecular pain.

[15]  A. Kolokoltsov,et al.  CCK2 receptor expression transforms non‐tumorigenic human NCM356 colonic epithelial cells into tumor forming cells , 2009, International journal of cancer.

[16]  L. Miller,et al.  CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours , 2009, Journal of cellular and molecular medicine.

[17]  S. Watson,et al.  Targeting of CCK-2 Receptor–Expressing Tumors Using a Radiolabeled Divalent Gastrin Peptide , 2009, Journal of Nuclear Medicine.

[18]  T. Wang,et al.  Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. , 2009, The Journal of clinical investigation.

[19]  J. Alonso,et al.  Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth , 2009, Anti-cancer drugs.

[20]  Christopher O. McGovern,et al.  Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression , 2009, Pancreas.

[21]  E. Krenning,et al.  Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  J. Black.  Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer. , 2009, European journal of cancer.

[23]  O. Ogunwobi,et al.  Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. , 2008, Journal of molecular endocrinology.

[24]  O. Ogunwobi,et al.  Glycine-extended gastrin stimulates proliferation via JAK2- and Akt-dependent NF-κB activation in Barrett’s oesophageal adenocarcinoma cells , 2008, Molecular and Cellular Endocrinology.

[25]  K. Chayama,et al.  Role of the Gastrin-Gastrin Receptor System in the Expansive Growth of Human Gastric Neoplasms , 2008, Digestion.

[26]  J. Reubi,et al.  Peptide-Based Probes for Cancer Imaging , 2008, Journal of Nuclear Medicine.

[27]  F. Campbell,et al.  Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[28]  Jinzhong Liu,et al.  Immunohistochemical Examination of Gastrin, Gastrin Precursors, and Gastrin/CCK-2 Receptor in Human Esophageal Squamous Cell Carcinomas , 2008, Pathology & Oncology Research.

[29]  T. Morris,et al.  Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models , 2008, Regulatory Peptides.

[30]  B. Maigret,et al.  Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin , 2008, Regulatory Peptides.

[31]  R. Chin,et al.  Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis,and inhibits the proliferation of human gastric cancer cells in vitro , 2008 .

[32]  W. Oyen,et al.  Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. , 2008, European journal of nuclear medicine and molecular imaging.

[33]  Dan Li,et al.  [Effect of gastrin on tyrosine phosphorylation of focal adhesion kinase in human gastric cancer cell line SGC7901]. , 2008, Ai zheng = Aizheng = Chinese journal of cancer.

[34]  S. Watson,et al.  Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro , 2008, Cancer Chemotherapy and Pharmacology.

[35]  R. Jensen,et al.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. , 2007, Current opinion in pharmacology.

[36]  S. Watson,et al.  Role of gastrin peptides in carcinogenesis. , 2007, Cancer letters.

[37]  W. Oyen,et al.  Development and application of peptide-based radiopharmaceuticals. , 2007, Anti-cancer agents in medicinal chemistry.

[38]  G. Baldwin,et al.  CCK receptors and cancer. , 2007, Current topics in medicinal chemistry.

[39]  L. Miller,et al.  Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. , 2007, Current topics in medicinal chemistry.

[40]  S. Watson,et al.  Selection of Radiolabeled Gastrin Analogs for Peptide Receptor–Targeted Radionuclide Therapy , 2007, Journal of Nuclear Medicine.

[41]  Weigong Zhou,et al.  Cholecystokinin-a receptor messenger RNA expression in human pancreatic cancer , 1999, Journal of Gastrointestinal Surgery.

[42]  J. Reubi,et al.  Targeting CCK receptors in human cancers. , 2007, Current topics in medicinal chemistry.

[43]  S. Watson,et al.  Gastrin — active participant or bystander in gastric carcinogenesis? , 2006, Nature Reviews Cancer.

[44]  Wen-ling Wang,et al.  [Blocking the gastrin/cholecystokinin-B receptor autocrine loop influences the growth and apoptosis of human gastric cancer cells]. , 2006, Zhonghua yi xue za zhi.

[45]  T. Hickish,et al.  Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials , 2006, British Journal of Cancer.

[46]  D. Park,et al.  Expression of gastrin and its receptor in human gastric cancer tissues , 2006, Journal of Cancer Research and Clinical Oncology.

[47]  Y. Naito,et al.  Biomarkers in Patients with Gastric Inflammation: A Systematic Review , 2005, Digestion.

[48]  D. Acuña-Castroviejo,et al.  Selective CCK‐A but not CCK‐B receptor antagonists inhibit HT‐29 cell proliferation: synergism with pharmacological levels of melatonin , 2005, Journal of pineal research.

[49]  F. Schmitz,et al.  Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo. , 2005, Gastroenterology.

[50]  B. Evers.  Gastrointestinal growth factors and neoplasia. , 2005, American journal of surgery.

[51]  K. Choe,et al.  Growth effect of gastrin on gastric cancer and its clinical implications for gastric cancer surgery. , 2005, Oncology reports.

[52]  W. Meng,et al.  Expression of some tumor associated factors in human carcinogenesis and development of gastric carcinoma. , 2005, World journal of gastroenterology.

[53]  L. Miller,et al.  Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. , 2005, Cancer letters.

[54]  Chang-an Liu,et al.  Correlation between gene expression of CCK-A receptor and emptying dysfunction of the gallbladder in patients with gallstones and diabetes mellitus. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[55]  D. Wei,et al.  [Expression of gastrin in human gastric cancer cell line and effect of anti-gastrin mAb on the cell growth]. , 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[56]  Jin‐Young Jang,et al.  Presence of CCK-A, B receptors and effect of gastrin and cholecystokinin on growth of pancreatobiliary cancer cell lines. , 2005, World journal of gastroenterology.

[57]  C. Johnson,et al.  Gallbladder motility, gallstones, and the surgeon , 1995, Digestive Diseases and Sciences.

[58]  G. Poston,et al.  Early stages of gallstone formation in guinea pig are associated with decreased biliary sensitivity to cholecystokinin , 1992, Digestive Diseases and Sciences.

[59]  Jill P. Smith,et al.  Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990 , 1990, Digestive Diseases and Sciences.

[60]  E. Krenning,et al.  Candidates for peptide receptor radiotherapy today and in the future. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  J. Morisset.  The gastrointestinal cholecystokinin receptors in health and diseases. , 2005, Roczniki Akademii Medycznej w Bialymstoku.

[62]  L. Pradayrol,et al.  Expression of cholecystokinin-2/gastrin receptor in the murine pancreas modulates cell adhesion and cell differentiation in vivo. , 2004, The American journal of pathology.

[63]  I. Zagon,et al.  The Functional Significance of the Cholecystokinin-C (CCK-C) Receptor in Human Pancreatic Cancer , 2004, Pancreas.

[64]  J. Morisset,et al.  What are the pancreatic target cells for gastrin and its CCKB receptor? Is this a couple for cancerous cells? , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[65]  C. Townsend,et al.  Agonist-independent Activation of Src Tyrosine Kinase by a Cholecystokinin-2 (CCK2) Receptor Splice Variant* , 2004, Journal of Biological Chemistry.

[66]  Satish K. Singh,et al.  Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells , 2004, Regulatory Peptides.

[67]  S. Watson,et al.  The Biological and Therapeutic Importance of Gastrin Gene Expression in Pancreatic Adenocarcinomas , 2004, Cancer Research.

[68]  Steffen Mühldorfer,et al.  Activation of NFκB Represents the Central Event in the Neoplastic Progression Associated with Barrett's Esophagus: A Possible Link to the Inflammation and Overexpression of COX-2, PPARγ and Growth Factors , 2004, Digestive Diseases and Sciences.

[69]  L. Lovat,et al.  Gastrin-Induced Cyclooxygenase-2 Expression in Barrett’s Carcinogenesis , 2004, Clinical Cancer Research.

[70]  G. Baldwin,et al.  Gastrins, cholecystokinins and gastrointestinal cancer. , 2004, Biochimica et biophysica acta.

[71]  S. Watson,et al.  A phase II study of G17DT in gastric carcinoma. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[72]  S. Watson,et al.  An Antiapoptotic Role for Gastrin and the Gastrin/CCK-2 Receptor in Barrett’s Esophagus , 2004, Cancer Research.

[73]  S. Waldman,et al.  Human Cholecystokinin-A Receptor Is Not an Oncofetal Protein , 2000, Digestive Diseases and Sciences.

[74]  Jian-JiangZhou,et al.  Coexpression of cholecystokinin-B／gastrin receptor and gastrin gene in human gastric tissues and gastric cancer cell line , 2004 .

[75]  E. Hahn,et al.  Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. , 2004, Digestive diseases and sciences.

[76]  K. Shimazaki,et al.  Effect of endogenous hypergastrinemia on carcinogenesis in the rat esophagus , 2004, Surgery Today.

[77]  L. Miller,et al.  Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.

[78]  L. Pradayrol,et al.  High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor , 2003, Oncogene.

[79]  R. Herranz.  Cholecystokinin antagonists: Pharmacological and therapeutic potential , 2003, Medicinal research reviews.

[80]  H. Friess,et al.  Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. , 2003, Gastroenterology.

[81]  Chris Albanese,et al.  Gastrin-induced gastric adenocarcinoma growth is mediated through cyclin D1. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[82]  B. Cong,et al.  Expression and cell-specific localization of cholecystokinin receptors in rat lung. , 2003, World journal of gastroenterology.

[83]  K. Chihara,et al.  Oncogenic ras induces gastrin/CCKB receptor gene expression in human colon cancer cell lines LoVo and Colo320HSR. , 2003, The Journal of laboratory and clinical medicine.

[84]  D. Thompson,et al.  Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. , 2003, Gastroenterology.

[85]  E. Hahn,et al.  Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. , 2003, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[86]  J. Gutkind,et al.  Gastrin Stimulates Cyclooxygenase-2 Expression in Intestinal Epithelial Cells through Multiple Signaling Pathways , 2002, The Journal of Biological Chemistry.

[87]  I. Zagon,et al.  Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. , 2002, International journal of molecular medicine.

[88]  B. Ji,et al.  Human pancreatic acinar cells do not respond to cholecystokinin. , 2002, Pharmacology & toxicology.

[89]  T. Morris,et al.  Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence , 2002, British Journal of Cancer.

[90]  J. Rehfeld,et al.  Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. , 2002, Gastroenterology.

[91]  R. Jensen,et al.  Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. , 2002, Gastroenterology.

[92]  M. Béhé,et al.  Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. , 2002, Seminars in nuclear medicine.

[93]  J. Siegfried,et al.  Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. , 2002, Journal of the National Cancer Institute.

[94]  R. Palmiter,et al.  The Gastrin Receptor Promotes Pancreatic Growth in Transgenic Mice , 2002, Pancreas.

[95]  L. Miller,et al.  A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. , 2002, Cancer research.

[96]  T. Wang,et al.  Expression of CCK2 receptors in the murine pancreas: proliferation, transdifferentiation of acinar cells, and neoplasia. , 2002, Gastroenterology.

[97]  Y. Ogura,et al.  Inhibitory Effect of Loxiglumide (CR 1505), a CholecystokininReceptor Antagonist, onN-Nitrosobis(2-oxopropyl)amine-induced BiliaryCarcinogenesis in Syrian Hamsters , 2002, World Journal of Surgery.

[98]  M. Béhé,et al.  Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. , 2002, Biopolymers.

[99]  M. Ławniczak,et al.  Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2. , 2001, Medical Science Monitor.

[100]  T. Noda,et al.  Importance of CCK-A receptor for gallbladder contraction and pancreatic secretion: a study in CCK-A receptor knockout mice. , 2001, The Japanese journal of physiology.

[101]  F. Schmitz,et al.  CCK‐B/gastrin receptors in human colorectal cancer , 2001 .

[102]  T. Lehy,et al.  Glycine-extended gastrin promotes the invasiveness of human colon cancer cells. , 2001, Biochemical and biophysical research communications.

[103]  B. Ohlsson,et al.  Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines. , 2001, Scandinavian journal of gastroenterology.

[104]  J. Tredger,et al.  Use of a novel CCKB/gastrin receptor antagonist, gastrazole (JB5008) in patients with advanced pancreatic adenocarcinoma. Results of an open labeled pilot trial , 2001 .

[105]  S. Watson,et al.  Expression of gastrin in developing gastric adenocarcinoma , 2001, The British journal of surgery.

[106]  A. Gilliam,et al.  G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy , 2001, Expert opinion on biological therapy.

[107]  S. Srinivasan,et al.  Molecular mechanisms for the antiapoptotic action of gastrin. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[108]  A. Dhillon,et al.  Expression and processing of gastrin in pancreatic adenocarcinoma , 2002, The British journal of surgery.

[109]  S. Watson,et al.  Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence , 2000, Gut.

[110]  T. Morris,et al.  Antiserum raised against an epitope of the cholecystokinin B/gastrin receptor inhibits hepatic invasion of a human colon tumor. , 2000, Cancer research.

[111]  H. Hellmich,et al.  Human Colorectal Cancers Express a Constitutively Active Cholecystokinin-B/Gastrin Receptor That Stimulates Cell Growth* , 2000, The Journal of Biological Chemistry.

[112]  E. Krenning,et al.  Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma , 2000, European Journal of Nuclear Medicine.

[113]  J. Rehfeld,et al.  Closing the gastrin loop in pancreatic carcinoma , 2000, Cancer.

[114]  V. Villanacci,et al.  Inhibitory Effect of a Gastrin Receptor Antagonist, CR2945, on 1,2-Dimethylhydrazine-Induced Colorectal Cancer in Mice , 1999, European Surgical Research.

[115]  G. Baldwin,et al.  Expression of gastrin/CCK-B receptors does not lead to a mitogenic response to gastrin in two colon cell lines. , 1999, The Journal of surgical research.

[116]  M. Hollingsworth,et al.  Cholecystokinin A and B receptor mRNA expression in human pancreas. , 1999, Pancreas.

[117]  M. Béhé,et al.  Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[118]  J. Laissue,et al.  Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located? , 1999, International journal of cancer.

[119]  R. Lei,et al.  [Correlation between gene expression of CCK-A receptor and gallbladder emptying in gallstone patients]. , 1999, Zhonghua wai ke za zhi [Chinese journal of surgery].

[120]  E. Rozengurt.  Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. , 1999, Current opinion in oncology.

[121]  A. Funakoshi,et al.  Mechanism of Cholecystokinin-A- Receptor Antagonist on Human Pancreatic Exocrine Secretion , 1999, Digestion.

[122]  L. Dethloff,et al.  Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[123]  J. P. Smith,et al.  Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. , 1998, Cancer letters.

[124]  A. Andrén-sandberg,et al.  Other risk factors for pancreatic cancer: hormonal aspects. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  B. Evers,et al.  JMV1155: a novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. , 1999, Anticancer research.

[126]  M. Löhr,et al.  Human pancreatic cancer cell lines express the CCKB receptor. , 1999, Hepato-gastroenterology.

[127]  J. Reubi,et al.  High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. , 1999, The Journal of clinical endocrinology and metabolism.

[128]  K. Shen,et al.  Effects of proglumide, a gastrin receptor antagonist, on human large intestine carcinoma SW480 cell line. , 1998, Chinese medical journal.

[129]  C. Michejda,et al.  Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[130]  J. P. Smith,et al.  Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas. , 1998, International journal of molecular medicine.

[131]  P. Towner,et al.  Cholecystokinin receptors in human pancreatic cancer cell lines. , 1998, European journal of cancer.

[132]  G. Friedman,et al.  Gastrin and colorectal cancer: a prospective study. , 1998, Gastroenterology.

[133]  T. Yasuda,et al.  [Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[134]  S. Watson,et al.  Coexpression of gastrin and gastrin receptors (CCK-B and ΔCCK-B) in gastrointestinal tumour cell lines , 1998, Gut.

[135]  G. Baldwin,et al.  Gastrin, gastrin receptors and colorectal carcinoma , 1998, Gut.

[136]  J. P. Smith,et al.  Characterization of CCK-B/gastrin-like receptors in human gastric carcinoma. , 1998, International journal of oncology.

[137]  N. Vaysse,et al.  Differential expression of the CCK‐A and CCK‐B/gastrin receptor genes in human cancers of the esophagus, stomach and colon , 1997, International journal of cancer.

[138]  T. Wang,et al.  Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. , 1997, Gastroenterology.

[139]  S. Waldman,et al.  Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. , 1997, The Journal of clinical investigation.

[140]  P. de Micco,et al.  The human gastrin/cholecystokinin receptors: type B and type C expression in colonic tumors and cell lines. , 1997, Life sciences.

[141]  M. D'Amato,et al.  Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders. , 1997, Expert opinion on investigational drugs.

[142]  C. Lamers,et al.  Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas. , 1997, British Journal of Cancer.

[143]  C. Sperti,et al.  Clinical Evaluation and Safety of Loxiglumide (CCK‐A Receptor Antagonist) in Nonresectable Pancreatic Cancer Patients , 1997 .

[144]  J C Reubi,et al.  Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. , 1997, Cancer research.

[145]  K. Detjen,et al.  Transfected cholecystokinin receptors mediate growth inhibitory effects on human pancreatic cancer cell lines. , 1997, Gastroenterology.

[146]  J. Rehfeld,et al.  Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. , 1997, Gastroenterology.

[147]  C. Sperti,et al.  Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group. , 1997, Pancreas.

[148]  J. Gardner,et al.  Gastrin and colon cancer: a unifying hypothesis. , 1996, Digestive diseases.

[149]  T. Noda,et al.  G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[150]  N. Iwata,et al.  Autocrine loop through cholecystokinin-B/gastrin receptors involved in growth of human leukemia cells. , 1996, Blood.

[151]  M. Imamura,et al.  Evaluation of cholecystokinin, gastrin, CCK-A receptor, and CCK-B/gastrin receptor gene expressions in gastric cancer. , 1996, Cancer letters.

[152]  I. Modlin,et al.  The gastric enterochromaffin-like cell: an enigmatic cellular link. , 1996, Gastroenterology.

[153]  J. P. Smith,et al.  Characterization of the CCK-B/gastrin-like receptor in human colon cancer. , 1996, The American journal of physiology.

[154]  C. Lamers,et al.  Cholecystokinin receptors in human pancreas and gallbladder muscle: A comparative study , 1996, Regulatory Peptides.

[155]  J. P. Smith,et al.  Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. , 1996, The American journal of physiology.

[156]  D. Morris,et al.  DOSE DEPENDENT IN VIVO INHIBITION OF HUMAN COLORECTAL CANCER (LoVo) BY THE GASTRIN RECEPTOR ANTAGONIST, CI‐988 , 1996, Clinical and experimental pharmacology & physiology.

[157]  T. Chiba.  [Gastrin and gastrin receptor]. , 1996, Nihon rinsho. Japanese journal of clinical medicine.

[158]  L. Howes,et al.  Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo and in vitro. , 1996, The Australian and New Zealand journal of surgery.

[159]  R. Håkanson,et al.  Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. , 1996, Scandinavian journal of gastroenterology.

[160]  T. Morris,et al.  Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. , 1996, Cancer research.

[161]  R. Bold,et al.  Progress toward hormonal therapy of gastrointestinal cancer. , 1996, Annals of surgery.

[162]  J. Holst,et al.  Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats. , 1995, Gastroenterology.

[163]  G. Ciccotosto,et al.  Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. , 1995, Gastroenterology.

[164]  J. Robertson,et al.  Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer , 1995, International journal of cancer.

[165]  G. Baldwin,et al.  Expression of gastrin, gastrin/CCK-B- and gastrin/CCK-C. Receptors in human colorectal carcinomas , 1995 .

[166]  N. Iwata,et al.  Cholecystokinin-B/gastrin receptor: a novel molecular probe for human small cell lung cancer. , 1995, Cancer research.

[167]  S. Wank.  Cholecystokinin receptors. , 1995, The American journal of physiology.

[168]  J. P. Smith,et al.  Identification of gastrin as a growth peptide in human pancreatic cancer. , 1995, The American journal of physiology.

[169]  R. Jensen,et al.  Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors. , 1994, Gastroenterology.

[170]  R. Bold,et al.  Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B. , 1994, Biochemical and biophysical research communications.

[171]  T. Matsui,et al.  Gastrin Receptor Gene Expression in Several Human Carcinomas , 1994, Japanese journal of cancer research : Gann.

[172]  C. Seva,et al.  Growth-promoting effects of glycine-extended progastrin. , 1994, Science.

[173]  B. Hirst,et al.  Autocrine growth stimulation of human renal Wilms' tumour G401 cells by a gastrin‐like peptide , 1994, International journal of cancer.

[174]  S. Wank,et al.  Cholecystokinin Receptor Family , 1994 .

[175]  J. Behar,et al.  Cholecystokinin-coupled intracellular signaling in human gallbladder muscle. , 1994, Gastroenterology.

[176]  P. Malfertheiner,et al.  Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction. , 1994, The American journal of gastroenterology.

[177]  C. Niederau,et al.  Effects of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells. , 1994, Anticancer research.

[178]  J. P. Smith,et al.  Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. , 1994, The American journal of physiology.

[179]  J. Rehfeld,et al.  The tumor biology of gastrin and cholecystokinin. , 1994, Advances in cancer research.

[180]  S. Wank,et al.  Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. , 1994, Annals of the New York Academy of Sciences.

[181]  K. Lillemoe,et al.  Physiology and pathophysiology of gallbladder motility. , 1993, The Surgical clinics of North America.

[182]  R. Bold,et al.  Biomolecular advances in gastrointestinal hormones. , 1993, Archives of surgery.

[183]  J. P. Smith,et al.  Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. , 1993, The American journal of physiology.

[184]  C. Laboisse,et al.  Evidence for autocrine growth stimulation by a gastrin/CCK-like peptide of the gastric cancer HGT-1 cell line , 1993, Molecular and Cellular Endocrinology.

[185]  C. Esquivel,et al.  Characterization of cholecystokinin receptors on the human gallbladder. , 1993, Surgery.

[186]  B. Hirst,et al.  Autocrine stimulation of growth of AR4-2J rat pancreatic tumour cells by gastrin. , 1992, British journal of cancer.

[187]  C. Townsend,et al.  The effect of gastrin on growth of human stomach cancer cells. , 1992, Annals of surgery.

[188]  G. Baldwin,et al.  Measurement of gastrin and transforming growth factor alpha messenger RNA levels in colonic carcinoma cell lines by quantitative polymerase chain reaction. , 1992, Cancer research.

[189]  B. Levin,et al.  A Pilot Clinical Trial of the Cholecystokinin Receptor Antagonist MK‐329 in Patients with Advanced Pancreatic Cancer , 1992, Pancreas.

[190]  Jill P. Smith,et al.  CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium , 1991, Regulatory Peptides.

[191]  D. Morris,et al.  The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma , 1990, Cancer.

[192]  T. Solomon,et al.  Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA PaCa-2. , 1990, Gastroenterology.

[193]  P. Kiener,et al.  Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide. , 1990, Experimental cell research.

[194]  C. Townsend,et al.  Effects of gastrointestinal peptides on gastrointestinal cancer growth. , 1989, Gastroenterology clinics of North America.

[195]  S. Watson,et al.  The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin , 1989, International journal of cancer.

[196]  S. Watson,et al.  Gastrin: growth enhancing effects on human gastric and colonic tumour cells. , 1989, British Journal of Cancer.

[197]  R. Woutersen,et al.  Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. , 1989, Gastroenterology.

[198]  Pomila Singh,et al.  Clinical significance of gastrin receptors in human colon cancers. , 1989, Cancer research.

[199]  D. Morris,et al.  Growth‐promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro , 1988, The British journal of surgery.

[200]  W. Nealon,et al.  Correlation of cholecystokinin receptors with gallbladder contractility in patients with gallstones. , 1987, Annals of surgery.

[201]  J. Lamote,et al.  Effect of cholecystokinin-octapeptide, caerulein, and pentagastrin on epithelial cell proliferation in the murine gallbladder. , 1982, Gastroenterology.

[202]  G. Fried,et al.  Correlation between Release of Cholecystokinin and Contraction of the Gallbladder in Patients with Gallstones , 1982, Annals of surgery.

[203]  J. Thompson,et al.  Release of Cholecystokinin in Man: Correlation of Blood Levels with Gallbladder Contraction , 1981, Annals of surgery.

[204]  L. Johnson.  Effects of gastrointestinal hormones on pancreatic growth , 1981, Cancer.

[205]  P. Zentler-Munro,et al.  Gall-bladder sensitivity to cholecystokinin in patients with gall stones. , 1980, British medical journal.

[206]  L. Johnson,et al.  Stimulation of pancreatic growth by secretin, caerulein, and pentagastrin. , 1980, Endocrinology.

[207]  J. Elashoff,et al.  Interaction of caerulein and secretin on pancreatic size and composition in rat. , 1978, The American journal of physiology.

[208]  K. Winckler,et al.  Influence of repeated administration of cholecystokinin and secretin on the pancreas of the rat. , 1978, Scandinavian journal of gastroenterology.

[209]  P. D. Webster,et al.  Hormonal control of pancreatic growth. , 1973, The Journal of clinical investigation.

[210]  S. Rothman,et al.  Enhancement of pancreatic enzyme synthesis by pancreozymin. , 1967, The American journal of physiology.